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1 
Tables 
Marker Meaning Unit LLOQ ULOQ  Intra/Inter assay variability 
C1M Type I collagen degraded by 
MMP-2/9/13 
ng/ml 21.2 421.0 ≤ 13.7 % and ≤ 20.8 % 
C3M Type III collagen degraded by 
MMP-9 
ng/ml 6.4 217.5 ≤ 13.5 % and ≤14.5 % 
C3A Type III collagen degraded by 
ADAMTS-1/4/8 
ng/ml 10.8 450.0 ≤ 2.0 % and ≤ 2.5 % 
C5M Type V collagen degraded by 
MMP-2/9 
ng/ml 17.3 2400 ≤ 6.5 % and ≤ 7.5% 
C6M Type VI collagen degraded by 
MMP-2/9 
ng/ml 5.2 267.6 ≤ 6.2 % and ≤ 11.6% 
ELM Elastin degraded by MMP-12 ng/ml 4.5 391.1 ≤ 8.2 % and ≤12.7 % 
ELM2 Elastin degraded by MMP-9/12 ng/ml 5.4 207.4 ≤ 15.5 % and ≤ 14.5 % 
VICM Citrullinated vimentin degraded 
by MMP-2/8  
ng/ml 0.8 85.2 ≤ 7.2 % and ≤15 % 
BGM Biglycan degraded by MMP-2/9 ng/ml 2.4 400 ≤20.4 % and ≤ 20.9 % 
CRPM MMP degraded CRP-1/8 ng/ml 3.2 110.0 ≤ 11.1 % and ≤20.8 % 
P3NP Type III collagen formation ng/ml 4.0 120.2 ≤ 8.2 % and ≤17.8 % 
LLOQ- Lower Limit of Quantification, ULOQ- Upper Limit of Quantification 
Supplementary Table 1. Assay performance characteristics and the upper and lower limits of 
quantification for each neoepitope. 
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Brompton (n=91) Nottingham (n=98) All subjects (n=189) 
Age (years) 67.7 (8.60) 72.2 (7.38) 70.1 (8.28) 
Male sex 75 (82.4%) 74 (75.5%) 149 (78.8%) 
Ethnicity 
European 80 (87.9%) 98 (100%) 178 (94.2%) 
Asian 10 (11.0%) 0 (0%) 10 (5.3%) 
Other 1 (1.1%) 0 (0%) 1 (0.5) 
Ever smokers 63 (69.2%)  72 (73.5%) n=97 134 (70.9%) n=188 
BMI (Kg/m2) 28.1 (4.27) 28.6 (4.50) 28.4 (4.39) 
Baseline lung function 
FVC %predicted 71.1 (19.4) n=87 83.1 (17.2) n=97 77.5 (19.2) n=184 
FVC 60≤90 % predicted 47 (51.6) 62 (63.3) 109 (57.7) 
DLco % predicted 40.5 (14.3) n=86 45 (15.5) n=90 42.8 (15.1) n=176 
DLco 60≤90 % predicted 29 (31.9) 35 (35.7) 64 (33.9) 
CPI 51.9 (12.9) n=86 46.8 (13.0) n=89 49.3 (13.2) n=175 
Data are Mean (SD) or number (%) unless otherwise stated. BMI – Body mass index. FVC – forced 
vital capacity, DLco – diffusion capacity for carbon monoxide. CPI – Composite Physiological Index. 
Supplementary Table 2. Comparison of baseline clinical characteristics between PROFILE subjects by 
recruitment centre (Brompton or Nottingham). 
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Variable Statistic/Level 
Discovery 
(N=20) 
Validation 
(N=50) 
Age N 20 50 
Age Mean (SD) 56.6 (4.57) 63.6 (8.03) 
Age Median (Q1-Q3) 56.0 (52.5-61.0) 64.5 (57.0-68.0) 
Age Min - Max 50.0-64.0 50.0-82.0 
Gender Female (%) 4 (20.0) 10 (20.0) 
Gender Male (%) 16 (80.0) 40 (80.0) 
Supplementary Table 3. Summary Statistics for age and gender within the control groups in the 
Discovery and Validation cohorts. 
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Model Variable Baseline/Gradient 
Hazard Ratio 
(95% CI) P value 
1 DLco BL 0.19 (0.09 ,0.40) <.0001 
FVC BL 0.76 (0.23 ,2.51) 0.66 
2 DLco BL 0.18 (0.09 ,0.36) <.0001 
BGM GR 1.07 (1.00 ,1.15) 0.048 
3 DLco BL 0.17 (0.09 ,0.34) <.0001 
C1M GR 1.01 (1.00 ,1.02) 0.012 
4 DLco BL 0.16 (0.08 ,0.32) <.0001 
C3A GR 1.05 (1.01 ,1.10) 0.016 
5 DLco BL 0.16 (0.08 ,0.32) <.0001 
C3M GR 1.10 (1.04 ,1.17) 0.0013 
6 DLco BL 0.18 (0.09 ,0.35) <.0001 
C5M GR 1.00 (1.00 ,1.00) 0.0036 
7 DLco BL 0.17 (0.09 ,0.33) <.0001 
C6M GR 1.04 (1.01 ,1.08) 0.014 
8 DLco BL 0.18 (0.09 ,0.35) <.0001 
CRPM GR 1.33 (1.10 ,1.60) 0.0034 
9 DLco BL 0.17 (0.09 ,0.34) <.0001 
VICM GR 1.01 (0.99 ,1.03) 0.20 
Supplementary Table 4. The effects of the magnitude of 3 month change in neoepitopes when 
combined with baseline DLco in multiple linear regression.  Baseline (BL) variables and longitudinal 
gradient (GR) variables are on different scales: lung function measures were transformed using a 
base 2 logarithm and the hazard ratio (HR ) for FVC and DLco relates to the change in hazard when 
these measurements increase two-fold.  The neoepitope gradients are on the original linear scale 
and so the hazard ratio for these variables relates to the change in hazard for every unit increase in 
the slope.  All analyses are adjusted for age, site and smoking status. 
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Gradient to Month 1 Gradient to Month 3 Gradient to Month 6 
Marker HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
BGM 1.007 (0.978, 1.037) 0.65 1.084 (1.030, 1.141) 0.0019 1.142 (1.041, 1.252) 0.0050 
C1M 1.001 (0.996, 1.005) 0.74 1.010 (1.003, 1.017) 0.0039 1.012 (1.006, 1.018) 0.0002 
C3A 1.006 (0.982, 1.031) 0.62 1.038 (0.989, 1.090) 0.13 1.039 (0.983, 1.099) 0.18 
C3M 1.020 (0.975, 1.067) 0.39 1.106 (1.045, 1.170) 0.0005 1.112 (1.054, 1.174) 0.0001 
C5M 1.001 (1.000, 1.003) 0.078 1.003 (1.001, 1.005) 0.0011 1.003 (1.001, 1.005) 0.0016 
C6M 1.011 (0.997, 1.025) 0.14 1.042 (1.007, 1.078) 0.017 1.049 (1.016, 1.082) 0.0028 
CRPM 1.145 (1.032, 1.271) 0.01 1.379 (1.164, 1.634) 0.0002 1.395 (1.178, 1.651) 0.0001 
VICM 1.014 (0.999, 1.030) 0.072 1.015 (0.998, 1.032) 0.080 1.016 (1.001, 1.032) 0.043 
Supplementary Table 5. The effects of the change in neoepitopes compared with overall survival.  
The association between the gradient to month 1, 3 and 6 and survival in the validation cohort are 
presented.  The gradients are on the original linear scale and so the hazard ratio for these variables 
relates to the change in hazard for every unit increase in the slope.  
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Figure Legends 
Supplementary Figure 1: Baseline comparison of neoepitope levels in healthy controls and IPF 
subjects in the discovery cohort. Patients were recruited into the PROFILE study within six months 
of diagnosis (baseline) and serum samples stored for biomarker analysis. Biomarker data from the 
Discovery Cohort are presented as means (ng/ml) and 95% confidence intervals adjusted for age and 
gender. Numbers in each group are: 20 healthy subjects (gender matched only) represented by ‘●’; 
and 55 subjects with IPF represented by ‘■’. For ELM2 4% of values respectively were imputed. For 
all other epitopes the imputation rate was <1%.  P values are provided where significant differences 
were observed between healthy subjects and IPF subjects. 
Supplementary Figure 2: Pooled Analysis from the discovery and validation cohort of baseline 
neoepitope levels in healthy controls and IPF subjects with stable and progressive disease. 
Combined numbers at baseline were 70 healthy subjects (●); 83 IPF subjects with stable disease (■) 
and 103 subjects with progressive IPF (▲).   Three subjects for C3A and one for VICM were excluded 
due to missing baseline samples.  Pooled biomarker data is presented as adjusted (least-squares) 
means (ng/ml) and 95% confidence intervals.  These estimates were adjusted for age, cohort and 
age by cohort interaction. Disease progression was defined as all-cause mortality or ≥ 10% decline in 
FVC at 12 months. P values are presented where significant differences were observed between 
Healthy subjects and Stable IPF subjects (□); between healthy subjects and progressive IPF (∆) and 
between stable IPF and progressive IPF (◊).  P values are based on the pair-wise comparison 
between groups, adjusted for age, cohort and age by cohort interaction.   The pooled analysis shows 
that there is a significant difference between levels of C1M and C6M in stable IPF patients and 
healthy controls.  Levels of BGM, C1M, C3M, C6M, CRPM and VICM are significantly higher in 
progressive IPF patients compared to controls.  Between progressive and stable IPF patients, levels 
of C3A, C3M, C6M, CRPM and VICM are significantly increased. 
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Supplementary Figure 3: Sensitivity analysis for the comparison of neoepitope levels in healthy 
controls and IPF subjects with stable and progressive disease at baseline and at 1, 3 and 6 months 
post baseline in the validation cohort.  Disease progression was defined as all-cause mortality or 
≥10% decline in FVC at 12 months. There were 16 cases without lung function data beyond baseline, 
so cases were adjudicated, following case note review, by the local principal investigator blinded to 
biomarker results.  In the sensitivity analysis, these cases were removed leaving  50 IPF subjects with 
stable disease (■) and 65 subjects with progressive IPF (▲). Biomarker data represent means 
(ng/ml) and 95% confidence intervals, adjusted for age and gender.  P values are provided where 
differences were observed between stable and progressive disease at a particular time point (◊). 
This sensitivity analysis supports the original analysis (Figure 3) by showing that levels of BGM, C1M, 
C3A, C3M, C6M and CRPM increase over time in the subjects with progressive, but not stable, 
disease. 
Supplementary Figure 4: Kaplan-Meier plot showing overall survival for the PROFILE IPF cohort. 
Curves are shown for the whole PROFILE IPF cohort of 189 subjects ( ) and are broken down in to 
those for the discovery ( ) (n=55) and validation cohorts ( ) (n=134). There was no significant 
difference in survival between cohorts. Mortality data were available for all subjects and were 
collected from the NHS registry with a date of censoring of 1st October 2013. 
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